SCHEMBL24423445

SCHEMBL24423445

COc1cc(-c2cc(C(=O)N3CCC(C(=O)O)CC3)n[nH]2)c(F)cn1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ FFAR4 Q5NUL3 1/20 0.38
▸ KDM5A P29375 8/20 0.37
▸ TBK1 Q9UHD2 2/20 0.37
▸ RAB9A P51151 1/20 0.36
▸ CPS1 P31327 1/20 0.36
▸ CCNT1 O60563 3/20 0.36
▸ CDK9 P50750 3/20 0.36
▸ CDK1 P06493 1/20 0.36
▸ CDK4 P11802 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ CDK8 P49336 1/20 0.36
▸ CDK7 P50613 1/20 0.36
▸ CDK6 Q00534 1/20 0.36
▸ MC4R P32245 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29584681 1.00 GAA (0.40) GAAKMT2AFFAR4KDM5ATBK1
SCHEMBL29585699 0.91 ALDH1A1 (0.41) KMT2AFFAR4KDM5ATBK1RAB9A
SCHEMBL24423866 0.88 GAA (0.40) GAAKMT2AKDM5ARAB9A
SCHEMBL29585378 0.88 NPC1 (0.48) GAAKMT2ARAB9A
SCHEMBL24423905 0.88 NPC1 (0.48) GAAKMT2ARAB9A
SCHEMBL24424363 0.87 FFAR4 (0.37) FFAR4KDM5ATBK1CCNT1CDK9
SCHEMBL24422914 0.87 ALDH1A1 (0.39) KMT2AKDM5ARAB9A
SCHEMBL29585218 0.87 NPC1 (0.40) KMT2ATBK1RAB9A
SCHEMBL24423814 0.85 MEN1 (0.46) KMT2AKDM5A
SCHEMBL24423815 0.85 MEN1 (0.46) KMT2AKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 — — US disclosed
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 — — EP disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 — — CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 — — US disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 — — US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 — — WO disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD GAA 2221/4885KMT2A 4267/4885FFAR4 25/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD GAA 3930/4885KMT2A 2698/4885FFAR4 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback